EU · EudraLex Vol.4
EU GMP Annex 1 9.46
9. Environmental & process monitoring › Aseptic process simulation (APS) (also known as media fill)
Section text
The target should be zero growth. Any contaminated unit should result in a failed APS and the following actions should be taken:
i. An investigation to determine the most probable root cause(s).
ii. Determination and implementation of appropriate corrective measures.
iii. A sufficient number of successful, consecutive repeat APS (normally a minimum of 3) should be conducted in order to demonstrate that the process has been returned to a state of control.
iv. A prompt review of all appropriate records relating to aseptic production since the last successful APS.
a) The outcome of the review should include a risk assessment of potential sterile breaches in batches manufactured since the last successful APS.
b) All other batches not released to the market should be included in the scope of the investigation. Any decision regarding their release status should consider the investigation outcome.
v. All products that have been manufactured on a line subsequent to a process simulation failure should be quarantined until a successful resolution of the process simulation failure has occurred.
vi. Where the root cause investigation indicates that the failure was related to operator activity, actions to limit the operator’s activities, until retrained and requalified, should be taken.
vii. Production should resume only after completion of successful revalidation.
Source: European Commission, DG SANTE · © European Union. Reuse is authorised provided the source is acknowledged (Commission Decision 2011/833/EU on the reuse of Commission documents). · retrieved 2026-11-15